Abstract: An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.

Abstract: The invention relates to spore specific antibodies. Compositions and methods relating to the antibodies are provided along with the hybridomas that produce the antibodies. The antibodies are specific for the spores of Bacillus anthracis relative to the vegetative form of the cells. The antibodies are also specific for the spores relative to other Bacillus spores and cells. The antibodies may be used to detect the presence of Bacillus anthracis spores by use of methods provided herein. The invention also relates to articles of manufacture as well as kits comprising these antibodies which may be used in the detection methods of the invention.

Abstract: The present invention provides a method of producing a dipeptide from starting materials that are available at low costs through a route industrially advantageous and simple. Dipeptides are produced from amino acid esters and amino acids by using a culture of a microbe having an ability to produce a dipeptide from an amino acid ester and an amino acid, microbial cells separated from the culture, or treated microbial cell product.

Abstract: The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured myceha and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

Abstract: Methods and devices for the detection of proteins secreted by the hyphal growth form of Candida species are disclosed. The disclosed devices may constitute a method for the diagnosis of acute or chronic infections, including candidiasis, caused by microorganisms of the species Candida, such as C. albicans, for example. The devices of the present invention incorporate antibodies specific to secreted aspartyl protease proteins whose expression is upregulated upon the conversion of the Candida species from the commensal to the pathogenic form. The antibodies may be used in assays to allow the diagnosis of candidal infections and disease conditions. Either monoclonal antibodies or polyclonal antibodies may be used, and in the case of the monoclonals, the specific epitopes of the SAP protein may be detected as well as the SAP protein itself.

Abstract: A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.

Abstract: The present invention provides a method for obtaining an immunogenic, non-haemolytic strain of Actinobacillus pleuropneumoniae which is modified, at least in a segment of the apxIA gene and optionally in a segment of the apxIIA gene that encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins. It comprises also the strains, and the attenuated live vaccine porcine pleuorpneumonia obtained therewith.

Abstract: Antigens are removed from the surface of an organism, such as a microorganism, without disrupting the organism and releasing internal antigens of the organism. The free surface antigens of the organism may be used to determine the presence of infection in an animal due to the organism by determining the presence of antibodies that bind to the free surface antigens in a sample obtained from the animal.

Abstract: The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.

Abstract: The present invention provides methods for determining whether a human being is susceptible to dental caries. The methods each include the steps of measuring the amount of ?-defensins HNP 1, HNP 2 and HNP 3 in saliva obtained from a human being, and determining whether a reduced amount of the ?-defensins HNP 1, HNP 2 and HNP 3 is present in the saliva, thereby determining whether the human being is susceptible to dental caries.

Abstract: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

Abstract: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.

Abstract: This application provides a method to establish and construct cell lines expressing pathogens without destruction of the host cells. The invention allows for the formation of cell lines for the purpose of continuous expression, release, and harvesting of the pathogen and maintain the consistency of the final biological pro duct. Although the invention is intended for pathogen antigen expression, the invention allows for the production of any antigen by the described methods. The establishment of a chronically infected celline can be used for reagent, diagnostic, quantification, or vaccine purposes. We have used the procedure to select for a host cell line that naturally adapts to HIV-1 replication without affecting the host cell's ability to survive. This allowed for the establishment of a chronic HIV-1 expressing cell line that continuously expresses HIV-1 particles.

Abstract: The present invention relates to an Immunogenic Complex comprising Ribosomal Complex and Adhesion of a Microbe or Ribosomal Complex and a viral antigen. The Ribosomal Complex is composed of the subunits of ribosomes (50 S and 30 S subunits in bacteria and 60 S and 40 S subunits of eucaryotes), the ribosomal subunits generally retaining sufficient integrity to preserve substantially the double-stranded nature of the large r-RNA's (16 S and 23 S in bacteria; 18 S and 28 S in eukaryotic cytosol) contained in the ribosomal subunits.

Abstract: The present invention relates to methods and assays for determining the presence of staphylococcal enterotoxin A in a sample through detection of a nucleic acid encoding staphylococcal enterotoxin A.

Abstract: Bacillus strains that inhibit pathogenic swine E. coli and/or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on the GRAS list. Bacillus species are sporeformers and therefore are highly stable and can be fed to swine.

Abstract: Methods and compositions for inducing an immune response against Pseudomonas aeruginosa are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and a Pseudomonas pilin peptide comprising an amino acid sequence that is TAADGLWKCTSDQDEQFIPKGCSK (SEQ ID NO.:1), wherein the chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said Pseudomonas pilin peptide to epithelial cells of said subject. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods of using chimeric immunogens of the invention.

Abstract: The present invention relates to nucleic acid sequences encoding a 22.5 kD Streptococcus uberis protein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 22.5 kD Streptococcus uberis protein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines.

Abstract: The present invention concerns a conjugation process for coupling a endotoxin (LPS) free polyfunctional polysaccharide with a polyfunctional carrier protein with quantitative yields. The invention also provides for vaccine formulations comprising the glyconjugate antigen manufactured by the process.

Abstract: A microorganism wherein one or more genes selected from the group of genes participating in sporulation in the middle to late stages of sporulation have been deleted or inactivated; and a process for producing a target product (a protein) by use the microorganism. No spore is formed when this microorganism is employed, thereby enabling production of a target product (a protein) while decreasing energy loss, production of a by-product and specific production speed to decrease unnecessary consumption of a medium. Moreover, the production period can be prolonged, whereby the target product (the protein) can be produced efficiently.